The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
The final analysis of the ROSEWOOD study compared a combination of zanubrutinib (a BTK inhibitor) plus obinutuzumab (ZO) versus obinutuzumab alone (O) in patients with relapsed/refractory follicular lymphoma (R/R FL) who had already received two or more prior treatments. With a medium follow-up of 34.6 months, ZO led to improved overall response rates (70% vs 44%) and higher complete responses (42% vs 19%) compared to obinutuzumab. The safety profile was generally manageable, with no new safety signals identified. The most common treatment-emergent adverse events (TEAEs) in the ZO arm were thrombocytopenia, COVID-19, diarrhea, and pneumonia. The most common TEAEs in the O arm were pyrexia, diarrhea, nausea, and neutropenia. Further evaluation of ZO in patients with R/R FL with one or more prior line of treatment compared to lenalidomide plus rituximab in the phase 3 MAHOGANY study is ongoing.
